There is a pattern to how these drugs get paid for in America, and it is now unmistakable. A manufacturer proves the molecule treats a condition that is not obesity. A regulator approves it for that condition. And a coverage door opens that the weight-loss exclusion does not close.
Cardiovascular disease was the first. Sleep apnea was the second. The liver is the third, and it may reach more people than either.
What MASH is, and why so few people know they have it
Fat accumulates in the liver. In some people it sits there quietly. In others it produces inflammation and cell injury — that is MASH — and over years that can progress to fibrosis, cirrhosis, and liver failure.
It is strongly associated with obesity, type 2 diabetes and metabolic syndrome. It is also almost entirely silent until it is advanced, which is why a very large number of people carrying it have no idea.
The trial that supported the approval measured what actually matters: resolution of steatohepatitis and improvement in fibrosis, rather than a change in a liver enzyme.
Why this matters more than the other new indications
Sleep apnea requires a sleep study. Cardiovascular indications require established cardiovascular disease, which is to say something has already gone badly wrong.
MASH sits differently. It is extremely common in exactly the population being denied coverage, it is diagnosable with non-invasive testing, and it is a genuine progressive disease that deserves treatment on its own terms rather than as a coverage manoeuvre.
The most useful sentence in American obesity medicine remains: find out what else you have. Not because it is a loophole, but because a great deal of it is undiagnosed.
What to ask for
If you have obesity or type 2 diabetes and have never had your liver assessed, that is a reasonable thing to raise. The usual sequence is liver enzymes and a non-invasive fibrosis score such as FIB-4, then elastography if that suggests risk.
Two honest cautions. Most people tested will not have advanced fibrosis, and going looking for a diagnosis in order to obtain a medication is not the right reason to be tested. The right reason is that untreated progressive liver disease is a serious thing to be carrying without knowing.
If you are tested, keep the numbers. Liver assessment is a trend rather than a snapshot — a FIB-4 score means considerably more alongside the one from eighteen months ago than it does alone, and these results scatter across portals and practices until nobody has the whole series. Zenday will hold them next to your weight and dose history, which is where they are most readable.
The pattern, stated plainly
We now have a system in which the same molecule, at the same dose, in the same body, is covered or excluded depending on which of four approved conditions your physician can document.
Each of those approvals represents real science and a real clinical benefit. It is also, unmistakably, a commercial strategy shaped by a payment system that will fund almost anything except the treatment of obesity itself.
Somebody with obesity, prediabetes, mild sleep apnea and early fibrosis is one patient with one metabolic problem. The system currently requires them to be four.